HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure.

AbstractAIMS:
Transferrin saturation (TSAT), a marker of iron deficiency, reflects both serum concentrations of iron (SIC) and transferrin (STC). TSAT is susceptible to changes in each of these biomarkers. Little is known about determinants of STC and its influence on TSAT and mortality in patients with heart failure. Accordingly, we studied the relationship of STC to clinical characteristics, to markers of iron deficiency and inflammation and to mortality in chronic heart failure (CHF).
METHODS AND RESULTS:
Prospective cohort of patients with CHF attending a clinic serving a large local population. A total of 4422 patients were included (median age 75 (68-82) years; 40% women; 32% with left ventricular ejection fraction ≤40%). STC ≤ 2.3 g/L (lowest quartile) was associated with older age, lower SIC and haemoglobin and higher high-sensitivity C-reactive protein, ferritin and N-terminal pro-brain natriuretic peptide compared with those with STC > 2.3 g/L. In the lowest STC quartile, 624 (52%) patients had SIC ≤13 μmol/L, of whom 38% had TSAT ≥20%. For patients in the highest STC quartile, TSAT was <20% when SIC was >13 μmol/L in 185 (17%) patients. STC correlated inversely with ferritin (r = -0.52) and high-sensitivity C-reactive protein (r = -0.17) and directly with albumin (r = 0.29); all P < 0.001. In models adjusted for age, N-terminal pro-brain natriuretic peptide and haemoglobin, both higher SIC (hazard ratio 0.87 [95% CI: 0.81-0.95]) and STC (hazard ratio 0.82 [95% CI: 0.73-0.91]) were associated with lower mortality. SIC was more strongly associated with both anaemia and mortality than either STC or TSAT.
CONCLUSIONS:
Many patients with CHF and a low STC have low SIC even when TSAT is >20% and serum ferritin >100 μg/L; such patients have a high prevalence of anaemia and a poor prognosis and might have iron deficiency but are currently excluded from clinical trials of iron repletion.
AuthorsFraser J Graham, Pierpaolo Pellicori, Gabriele Masini, Joseph J Cuthbert, Andrew L Clark, John G F Cleland
JournalESC heart failure (ESC Heart Fail) Vol. 10 Issue 5 Pg. 2826-2836 (10 2023) ISSN: 2055-5822 [Electronic] England
PMID37400990 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Chemical References
  • C-Reactive Protein
  • Ferritins
  • Hemoglobins
  • Iron
  • Transferrin
Topics
  • Aged
  • Female
  • Humans
  • Male
  • Anemia
  • Anemia, Iron-Deficiency (complications, diagnosis)
  • C-Reactive Protein
  • Chronic Disease
  • Ferritins (metabolism)
  • Heart Failure (complications, diagnosis)
  • Hemoglobins
  • Iron (metabolism)
  • Iron Deficiencies
  • Prospective Studies
  • Stroke Volume
  • Transferrin (metabolism)
  • Ventricular Function, Left
  • Aged, 80 and over

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: